156 related articles for article (PubMed ID: 38741123)
41. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
[TBL] [Abstract][Full Text] [Related]
42. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
43. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
[TBL] [Abstract][Full Text] [Related]
44. Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.
Koldehoff M; Kordelas L; Beelen DW; Elmaagacli AH
Haematologica; 2010 Mar; 95(3):388-97. PubMed ID: 20207846
[TBL] [Abstract][Full Text] [Related]
45. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
[TBL] [Abstract][Full Text] [Related]
46. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
[TBL] [Abstract][Full Text] [Related]
47. Targeted disruption of the
Zeng J; Liang X; Duan L; Tan F; Chen L; Qu J; Li J; Li K; Luo D; Hu Z
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):525-537. PubMed ID: 38414349
[TBL] [Abstract][Full Text] [Related]
48. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
49. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
50. Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates.
Shinkai Y; Kashihara S; Minematsu G; Fujii H; Naemura M; Kotake Y; Morita Y; Ohnuki K; Fokina AA; Stetsenko DA; Filichev VV; Fujii M
Nucleic Acid Ther; 2017 Jun; 27(3):168-175. PubMed ID: 28355131
[TBL] [Abstract][Full Text] [Related]
51. Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA.
Li MJ; McMahon R; Snyder DS; Yee JK; Rossi JJ
Oligonucleotides; 2003; 13(5):401-9. PubMed ID: 15000831
[TBL] [Abstract][Full Text] [Related]
52. Magnetic Nanoparticles PCR Enzyme-Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia.
Manthawornsiri Y; Polpanich D; Yamkamon V; Thiramanas R; Hongeng S; Rerkamnuaychoke B; Jootar S; Tangboriboonrat P; Jangpatarapongsa K
J Clin Lab Anal; 2016 Sep; 30(5):534-42. PubMed ID: 26667895
[TBL] [Abstract][Full Text] [Related]
53. Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.
Liu Y; Shao Z; Liao Y; Xia X; Huang C; He J; Hu T; Yu C; Jiang L; Liu J; Huang H
Eur J Pharmacol; 2020 Sep; 883():173366. PubMed ID: 32679184
[TBL] [Abstract][Full Text] [Related]
54. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
55. Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-
Singh A; Bhatia P
Curr Gene Ther; 2021; 21(3):270-277. PubMed ID: 33596804
[TBL] [Abstract][Full Text] [Related]
56. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
57. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
58. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
[TBL] [Abstract][Full Text] [Related]
59. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Mao JH; Sun XY; Liu JX; Zhang QY; Liu P; Huang QH; Li KK; Chen Q; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21683-8. PubMed ID: 21118980
[TBL] [Abstract][Full Text] [Related]
60. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
